Currently, postmenopausal ER+ breast cancer patients generally receive tamoxifen in sequence with an AI, or 5 years of an AI as adjuvant endocrine therapy for at least 5 years.3 Patients in our retrospective study received a maximum of 3 years of tamoxifen and no additional AI. Here, ESR1 is linked to breast carcinoma.